Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2019 Net Income-$5.49M-$5.49MN/M vs Q3 2019 EPS Diluted-$1.48-$1.48N/M vs Q3 2019 Operating Income-$5,410,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,148,000N/M ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end